Reports
Diabetes Clinical Trials Market Size, & Trend Analysis Report, 2026-2034
REPORT DETAILS
REPORT DETAILS
ABOUT THIS REPORT
Diabetes Clinical Trials Market Summary
The diabetes clinical trials market is estimated around USD 5.06 Billion in 2025,with consistent growth anticipated during 2026–2034. Rising diabetes prevalence, increasing pharmaceutical R&D investments, expansion of GLP-1 receptor agonist studies, and growing adoption of decentralized diabetes trials are driving market expansion globally. The market is projected to grow at a CAGR of 7.9% during the forecast period.
Market Statistics
Key Takeaways
- North America dominated the market in 2025 with 41.0% share, due to strong pharmaceutical R&D investments and advanced clinical research infrastructure.
- Phase III trials dominated the market in 2025 with 43.0% share, due to increasing late-stage commercialization studies for diabetes therapeutics.
- GLP-1 receptor agonist trials dominated the market in 2025 capturing 29.0% share driven by rising investment in obesity-linked diabetes therapies.
- Decentralized clinical trials are projected to grow at the fastest CAGR of 10.5% during the forecast period owing to increasing use of AI-enabled recruitment and remote patient monitoring systems.
- Major companies operating in the market include AbbVie Inc., AstraZeneca PLC, Biocon Limited, Boehringer Ingelheim International GmbH, Eli Lilly and Company, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc., Novo Nordisk A/S, Novartis AG, Pfizer Inc., Sanofi S.A., Servier Laboratories Pvt. Ltd.
Industry Dynamics
- Rising global diabetes prevalence is driving diabetes clinical trials market growth.
- Increasing commercialization of GLP-1 therapies is accelerating diabetes pipeline expansion.
- High clinical trial operational costs are restraining market growth.
- Growing adoption of AI-enabled decentralized diabetes studies is creating new market opportunities.
What is the Diabetes Clinical Trials Market?
Diabetes clinical trials involve research studies conducted to evaluate the safety, efficacy, and long-term outcomes of diabetes therapies, insulin products, biologics, medical devices, and metabolic disease treatments. These trials help to develop advanced treatments for Type 1 diabetes, Type 2 diabetes, diabetes caused by obesity, and related cardiovascular disorders. Clinical trials for diabetes drugs play an important role in the approval process, biomarker verification, and treatment optimization in the healthcare industry.
Clinical trials for diabetes represent a large and complex system comprising pharmaceutical organizations, biotech organizations, contract research organizations (CRO) services, regulatory bodies, clinical research organizations (CRO), technology vendors, among other stakeholders. Trial sponsors work in partnership with contract research organizations, digital health vendors, labs, and data analytic organizations to execute patient enrollment, protocol management, remote monitoring, and trial data analysis in different regions.
Diabetes clinical trials market is expected to grow on account of increasing prevalence of diabetes, obesity, and investments in metabolic disorder drug discovery. Growth in research involving GLP-1 receptor agonists, increasing use of wearables for monitoring blood glucose levels, and increasing investments in artificial intelligence-driven patient recruitment solutions are some of the factors contributing to market growth. Precision medicine & decentralized diabetes studies are gaining prominence thus driving industry growth.
Drivers & Opportunities
Rising Global Diabetes Burden is Driving Market Growth: There is rising presence of diabetes among developed and developing countries, hence high demand for novel diabetes drugs and research in metabolism diseases. The International Diabetes Federation reports that there are about 589 million adult people within the age bracket 20-79 living with diabetes worldwide in 2024, and an estimated diabetic population to grow to about 853 million by 2050.The rise in obesity, aging population, and sedentary lifestyle is expected to increase participation in Type 1 and Type 2 diabetes clinical trials.
Commercial Expansion of GLP-1 Therapies is Accelerating Clinical Trial Activity: The huge success of GLP-1 Receptor Agonists commercially is driving strategies for diabetes medicines research & development by various companies in the pharmaceutical industry. Investors are allocating more resources for the trials related to obesity-related diabetes and cardiometabolic indications along with trials combining incretin-based medicines. The increase in the number of clinical pipelines for semaglutide, tirzepatide, and other novel metabolic medicines is facilitating advanced diabetes medicine trials in their pipeline.
Restraints & Challenges
High Operational Costs and Patient Retention Challenges are Limiting Market Growth: The diabetes clinical trials involve significant costs as a result of the length of observation periods involved, the number of patients to be recruited and complicated compliance requirements, among others. The cardiovascular outcomes and the late-stage diabetes drugs also entail considerable cost considerations in terms of the difficulty in recruiting subjects, management of protocols as well as the length of the follow-up periods. The growing costs of data management also contribute to this.
Opportunity
AI-Driven Decentralized Diabetes Trials are Creating New Growth Opportunities: AI technologies and decentralization-based clinical trial models are enhancing patient enrollment and cutting down the time taken for conducting diabetes clinical trials. The University of Virginia conducted a clinical trial in February 2025 on an artificial intelligence-enabled diabetes treatment tool aimed at automating insulin delivery as well as glucose monitoring for patients suffering from type 1 diabetes.Remote monitoring systems, wearable glucose monitors, telemedicine software and AI-powered analytics software are facilitating diabetes clinical trials worldwide.
Segmental Insights
The report provides a comprehensive analysis of the diabetes clinical trials market by trial phase, study design, therapy type, and end user to identify key revenue generating and high-growth segments.
By Trial Phase
-
Phase III Trials
Phase III trials dominated the market in 2025 with 43.0% share due to rising commercialization activity for GLP-1 receptor agonists, insulin analogs, and cardiovascular outcome therapies. Clinical trials for diabetes in advanced stages include many patients worldwide, significant regulatory compliance considerations, and long-term efficacy monitoring.
-
Phase II Trials
Phase II trials are projected to grow at the fastest CAGR of 7.2% during the forecast period owing to increasing innovation in stem cell therapies, beta-cell replacement technologies, and diabetes biologics research. Biotechnology firms are expanding proof-of-concept studies targeting autoimmune diabetes and metabolic syndrome management.
Distribution of Trials by Phase
| Trial Phase | Share of Trials | Key Focus Area |
| Phase I | ~10% | Safety and dosage evaluation |
| Phase II | ~30% | Efficacy and treatment response |
| Phase III | ~45% | Large-scale validation and comparison |
| Phase IV | ~15% | Post-market surveillance and long-term outcomes |
By Study Design
-
Interventional Studies
Interventional studies dominated the market in 2025 with 64.0% share due to increasing regulatory approval requirements and rising demand for therapeutic efficacy validation across diabetes treatment pipelines. Sponsors continue expanding randomized diabetes studies to evaluate long-term glycemic control, cardiovascular safety, and metabolic outcomes.
-
Decentralized Clinical Trials
Decentralized clinical trials are projected to grow at the fastest CAGR of 10.5% during the forecast period owing to increasing use of wearable glucose monitoring devices, telemedicine integration, and remote patient engagement platforms. Virtual diabetes clinical trials improve patient accessibility, enrollment flexibility, and real-time monitoring capabilities across global research programs.
By Therapy Type
-
GLP-1 Receptor Agonist Trials
GLP-1 receptor agonist trials dominated the market with 29.0% share in 2025 driven by strong commercial adoption and increasing expansion into obesity-linked diabetes treatment studies. Investments in combinations therapies, cardiometabolic disease management programs & next-gen incretin-based therapies are some areas where pharma giants are making aggressive bets.
-
SGLT2 Inhibitor Trials
The SGLT2 inhibitor segment is expected to grow at the highest growth at a CAGR of 8.2% during the forecast period on account of greater emphasis on kidney protection, cardiovascular benefits, and metabolic diseases treatment. The SGLT2 inhibitors and GLP-1 receptor agonists combination treatment trials are carried out by sponsors for better patient benefits.
By End User
-
Pharmaceutical & Biotechnology Companies
Pharmaceutical and biotechnology firms have been dominating the market with 49.0% share in 2025 owing to robust diabetes therapeutic pipeline and rising R&D spending in metabolic diseases. Large pharmaceutical firms are expanding late-stage diabetes clinical programs, biologics development, and obesity-diabetes combination therapy studies.
-
Contract Research Organizations (CROs)
Contract research organizations are projected to grow at the fastest CAGR of 8.0% during the forecast period owing to rising outsourcing trends and increasing operational complexity across global diabetes studies. CROs are expanding site management, patient recruitment, regulatory support, and decentralized trial capabilities to improve operational efficiency.
Regional Analysis
North America Diabetes Clinical Trials Market Assessment
North America diabetes clinical trials market dominated the global market in 2025 capturing 41.0% share driven by strong pharmaceutical R&D infrastructure and high diabetes prevalence. According to the CDC National Diabetes Statistics Report published in March 2026, more than 40 million Americans are living with diabetes, including over 2 million individuals diagnosed with Type 1 diabetes.The US leads the region due to increasing investment in GLP-1 diabetes trials, obesity-linked metabolic disease studies, and AI-enabled clinical research platforms. Rising adoption of decentralized diabetes trials and wearable glucose monitoring technologies is supporting regional market growth.
Europe Diabetes Clinical Trials Market Overview
Europe diabetes clinical trials market held a significant share of 27.0% in 2025 driven by strong healthcare systems and growing precision medicine initiatives. In 2025, the European Commission launched the Beyond 1 Million Genomes Plus (B1MGplus) initiative to strengthen genomic and clinical data integration across Europe through a cross-border healthcare infrastructure program.Countries such as Germany, UK, and France are increasing investment in diabetes biologics trials and cardiovascular outcome studies. Growing support for advanced therapeutics development and digital clinical research infrastructure is supporting regional market expansion.
Asia Pacific Diabetes Clinical Trials Market Insights
Asia Pacific diabetes clinical trials market is projected to grow at the fastest CAGR of 10.0% during the forecast period due to rising diabetes incidence and expanding CRO ecosystems. According to the International Diabetes Federation, India recorded nearly 89.8 million adults living with diabetes in 2024, while the figure is projected to reach around 156.7 million by 2050.Countries including China, India, Japan, and South Korea are witnessing strong growth in diabetes patient recruitment and outsourced clinical research activities. Rising healthcare investments and pharmaceutical outsourcing are supporting regional market growth.
Latin America Diabetes Clinical Trials Market Overview
Latin America diabetes clinical trials market is witnessing steady growth owing to increasing healthcare investments and improving clinical research infrastructure across emerging economies. Countries such as Brazil, Mexico, and Argentina are expanding diabetes drug development programs and patient recruitment capabilities for multinational clinical studies. Growing focus on improving access to metabolic disease treatment is supporting regional market expansion.
Competitive Landscape
Key Players & Competitive Strategies
The diabetes clinical trials sector is very competitive owing to the expansion of the drug pipeline, more outsource work by CROs, and rising investments in obesity-related diabetes drugs. Competitiveness in the field depends on the efficacy of clinical trials, efficiency in enrolling patients into clinical studies, and regulatory competence. The firms are leveraging AI-powered patient recruitment, decentralized clinical trials, partnerships, and combination therapies to enhance their market positions.
Major companies operating in the diabetes clinical trials market include AbbVie Inc., AstraZeneca PLC, Biocon Limited, Boehringer Ingelheim International GmbH, Eli Lilly and Company, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc., Novo Nordisk A/S, Novartis AG, Pfizer Inc., Sanofi S.A., Servier Laboratories Pvt. Ltd., Takeda Pharmaceutical Company Limited, and Wockhardt Limited.
Premium Insights
The growing convergence between obesity therapeutics and diabetes treatment is expected to reshape the diabetes clinical trials landscape over the coming decade. Pharmaceutical organizations are making efforts in creating an integrated metabolic disorder platform with biological drugs, advanced diagnostics, artificial intelligence-based analytics and digital medicines to increase efficacy and monitoring of the patients.
The growing demand for GLP-1 receptor agonists, next-generation insulin, and combinations in metabolism is driving global clinical trials activity. Companies are increasingly opting for decentralized and hybrid clinical trial designs to facilitate better patient enrollment, improve retention rates, and minimize cost.
Wearable devices, continuous glucose monitoring, and prediction analytics are growing popular due to increasing importance as crucial tools for modern diabetes trials. The technologies are useful for capturing real-time data, monitoring compliance, and evaluating personalized treatments.
Organizations are able to enhance trial efficiency using AI-based patient identification techniques, remote monitoring, and effective patient recruitment is expected to have an enhanced competitive edge in the global diabetes clinical trials market.
Diabetes Prevalence vs Clinical Trial Density by Region
| Region | Diabetes Prevalence | Clinical Trial Density |
| North America | High | Very High |
| Europe | High | High |
| Asia Pacific | Very High | Rapidly Growing |
| Latin America | Medium | Moderate |
| Middle East & Africa | Growing | Low to Moderate |
Key Players
- AbbVie Inc.
- AstraZeneca PLC
- Biocon Limited
- Boehringer Ingelheim International GmbH
- Eli Lilly and Company
- GlaxoSmithKline PLC
- Johnson & Johnson
- Merck & Co., Inc.
- Novo Nordisk A/S
- Novartis AG
- Pfizer Inc.
- Sanofi S.A.
- Servier Laboratories Pvt. Ltd.
- Takeda Pharmaceutical Company Limited
- Wockhardt Limited
Industry Developments
- April 2026: The U.S. FDA approves first generic drugs of dapagliflozin tablets for the treatment of type 2 diabetes mellitus with cardiovascular benefits, providing wider access to SGLT2 inhibitors treatments and fortifying the diabetes therapeutics market in terms of commercial aspect. [source: fda.gov]
- February 2026: Eli Lilly and Company announced that its oral GLP-1 candidate orforglipron demonstrated superior blood sugar control and weight loss compared to oral semaglutide in a Phase III head-to-head type 2 diabetes trial. [source: lilly.com]
Diabetes Clinical Trials Market Segmentation
By Trial Phase Outlook (Revenue, USD Billion, 2021–2034)
- Phase I
- Phase II
- Phase III
- Phase IV
By Study Design Outlook (Revenue, USD Billion, 2021–2034)
- Interventional Studies
- Observational Studies
- Decentralized Clinical Trials
By Therapy Type Outlook (Revenue, USD Billion, 2021–2034)
- GLP-1 Receptor Agonists
- SGLT2 Inhibitors
- Insulin Analogs
- Gene Therapies
- Combination Therapies
- Others
By End User Outlook (Revenue, USD Billion, 2021–2034)
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations (CROs)
- Academic Research Institutes
- Hospitals & Specialty Clinics
By Regional Outlook (Revenue, USD Billion, 2021-2034)
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
Diabetes Clinical Trials Market Report Scope
| Report Attributes | Details |
| Market Size in 2025 | USD 5.06 Billion |
| Market Size in 2026 | USD 5.45 Billion |
| Revenue Forecast by 2034 | USD 10.02 Billion |
| CAGR | 7.9% from 2026 to 2034 |
| Base Year | 2025 |
| Historical Data | 2021–2024 |
| Forecast Period | 2026–2034 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2026 to 2034 |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Industry Trends |
| Segments Covered |
|
| Regional Scope |
|
| Competitive Landscape |
|
| Report Format |
|
| Customization | Report customization as per your requirements with respect to countries, regions, and segmentation. |
FAQ's
The global market size was valued at USD 5.06 Billion in 2025 and is projected to reach USD 10.02 Billion by 2034 at a CAGR of 7.9%.
Major growth drivers include rising diabetes prevalence, increasing GLP-1 therapy commercialization, AI integration, and growing adoption of decentralized diabetes trials.
Phase III trials dominated the market in 2025 with 43.0% share due to increasing late-stage commercialization programs for diabetes therapeutics.
North America dominated the market in 2025 with 41.0% share owing to advanced pharmaceutical infrastructure and strong diabetes R&D investments.
GLP-1 receptor agonists improve glycemic control and support obesity management, increasing global investment in cardiometabolic disease studies.
Asia Pacific is experiencing rapid growth at a CAGR of 10.0% due to large patient populations, lower operational costs, and expanding CRO outsourcing activities.
AI supports patient recruitment, protocol optimization, predictive analytics, biomarker discovery, and decentralized diabetes trial management.
Download Sample Report of Diabetes Clinical Trials Market
Please fill out the form to request a customized copy of the research report.
